CX3CL1 and primary biliary cholangitis: Although those with incomplete response to UDCA were enrolled in the study, as other clinical trials in PBC, histopathological findings revealed that most of the participating patients had pathologically advanced disease with bile duct loss, suggesting that the expression of FKN, which is the target of E6011, in the liver tissues might be scarce.